The reporting of CIMP positive or negative status in CRC patients, especially with BRAF mutations, has been recommended in the reporting guideline for molecular biomarkers established by an experts panel collaborated on by the American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO) [35]. Here, BRAF is linked to colorectal carcinoma.